FILED PURSUANT TO RULE 424(B)(5)
REGISTRATION NO. 333-113071
PROSPECTUS
NANOPIERCE TECHNOLOGIES, INC.
-----------------------------
370 17th Street, Suite 3640
Denver, Colorado 80202
82,600,000 SHARES OF COMMON STOCK, INCLUDING:
20,000,000 SHARES CURRENTLY OUTSTANDING
62,600,000 SHARES ISSUABLE UPON EXERCISE OF WARRANTS
THE SELLERS: All of our common stock offered by this prospectus is
offered from time to time by the selling stockholders
identified in this prospectus. We will not receive any
proceeds from the sale of our common stock offered by the
selling stockholders.
MARKET FOR
SECURITIES: Our common stock is presently quoted on the over-the-counter
bulletin board under the symbol "NPCT." Our common stock
also is traded on the Frankfurt Stock Exchange and on the
Hamburg Stock Exchange under the symbol "NPI." On January
27, 2005, the last reported sale price of our common stock
on the over-the-counter bulletin board was $0.16 per share
(rounded to the nearest penny). See "DESCRIPTION OF COMMON
STOCK-Common Stock."
RISK
FACTORS: INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF
RISK. SEE "RISK FACTORS" BEGINNING ON PAGE 5.
As of January 27, 2005, we have 91,259,033 shares of our common stock
issued and outstanding. The shares of common stock offered by this
prospectus represent about 46.05% of our issued and outstanding common
stock as of January 27, 2005, assuming that, as of that date, all of our
outstanding warrants and options were exercised and all of our reserved
shares of common stock were issued.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED ANY OF THESE SECURITIES
OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus is January 28, 2005.
TABLE OF CONTENTS
Page
-----
FORWARD-LOOKING STATEMENTS. . . . . . . . . . . . . . . . . . . . . . . . . 2
PROSPECTUS SUMMARY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
RISK FACTORS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
THE COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
USE OF PROCEEDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
DETERMINATION OF OFFERING PRICE . . . . . . . . . . . . . . . . . . . . . . 14
SELLING STOCKHOLDERS. . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
DESCRIPTION OF COMMON STOCK . . . . . . . . . . . . . . . . . . . . . . . . 17
PLAN OF DISTRIBUTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
EXPERTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
AVAILABLE INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
ADDITIONAL INFORMATION. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE . . . . . . . . . . . . . . 23
FORWARD-LOOKING STATEMENTS
This prospectus includes "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We base these forward-looking statements on our current
expectations and projections about future events. These forward-looking
statements are subject to risks, uncertainties, and assumptions about our
company, including:
- the rate of market development and acceptance of the interconnect
technology in the industry within which we are concentrating our
business activities;
- the limited revenues and significant operating losses generated to
date;
- the possibility of significant ongoing capital requirements and our
ability to secure financing as and when necessary;
- our ability to compete successfully with the other providers of
interconnect technologies or other lines of business that we may enter
into;
- our ability to retain the services of our key management, and to
attract new members of the management team; and
- our ability to obtain and retain appropriate patent, copyright and
trademark protection of our intellectual properties and any of our
products.
You should only rely on the information contained in this prospectus. We
have not authorized any person to provide you with different information. If
anyone provides you with different or inconsistent information, you should not
rely on it. The selling stockholders are not making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. You
should assume that the information appearing in this prospectus is accurate as
of the date on the front cover of this prospectus only. Our business, financial
condition, results of operations and prospects may have changed since that date.
2
PROSPECTUS SUMMARY
The following summary highlights certain information contained throughout
this prospectus. It is not complete and may not contain all of the information
that you should consider before investing in the securities offered by this
prospectus. To understand this offering fully, you should read this entire
prospectus carefully, including the risk factors. Before you make your
investment decision, you should also carefully read our attached annual report
on Form 10-KSB for our fiscal year ended June 30, 2004 and our quarterly report
on Form 10-QSB for the fiscal quarter ended September 30, 2004.
THE COMPANY
We were incorporated on June 22, 1996 as a Nevada corporation. Our
corporate offices are located at 370 - 17th Street, Suite 3640, Denver, Colorado
80202, and our telephone number is (303) 592-1010. We maintain a website at
www.nanopierce.com.
------------------
On February 26, 1998, we acquired the intellectual property rights related
to our patented Particle Interconnect Technology (the "particle technology")
from Particle Interconnect Corporation, a Colorado corporation, a wholly-owned
subsidiary of Intercell Corporation (now known as Intercell International
Corporation), a Nevada corporation that was our affiliate at the time of the
acquisition. We acquired the particle technology to pursue a more focused,
strategic application and development of the particle technology. We have
designated and are commercializing our particle technology as NCSTM. Since our
acquisition of the particle technology, we have focused on providing the
electronics industry with possible solutions to their "connection" problems.
On October 1, 2004, we signed a letter agreement (the "letter agreement")
with Xact Resources International, Inc. to provide for the development of a
joint venture between the company and Xact Resources International. The purpose
of the joint venture would be to produce, market and sell YBG-2000, a biotech
yeast beta glucan product which has been developed by Xact Resources. Our
participation in the joint venture depends on our ability to contribute cash in
the amount of $1.5 million and we cannot assure you that we will be successful
in raising the necessary capital. Pursuant to the letter agreement we have
advanced $225,000 to Xact Resources. See "THE COMPANY."
THE OFFERING
This offering includes 82,600,000 shares of our common stock, including:
- 20,000,000 shares outstanding as of the date of this prospectus
- 62,600,000 shares issuable upon the exercise of warrants owned by
the stockholders identified later in this prospectus
USE OF PROCEEDS
We will not receive any proceeds from the sale of the shares of our common
stock offered by this prospectus. See "USE OF PROCEEDS" for more information.
RISK FACTORS
Your investment in our common stock offered by this prospectus involves a
high degree of risk. See "RISK FACTORS" beginning on page 5.
SUMMARY CONSOLIDATED FINANCIAL DATA
The summary consolidated financial data shown below as of and for the three
months ended September 30, 2004 and 2003, have been derived from the unaudited
financial statements appearing in our quarterly report on Form 10-QSB for the
quarter ended September 30, 2004, which is incorporated by
3
reference into and accompanying this prospectus. The summary consolidated
financial data shown below for fiscal years ended June 30, 2004 and 2003 have
been derived from, and should be read in conjunction with, the consolidated
financial statements, related notes, and "MANAGEMENT'S DISCUSSION AND ANALYSIS"
appearing in our annual report on Form 10-KSB for the year ended June 30, 2004,
which is incorporated by reference into and accompanying this prospectus.
THREE MONTHS ENDED YEAR ENDED JUNE 30,
SEPTEMBER 30,
------------------------- -------------------------
2004 2003 2004 2003
------------ ----------- ----------- ------------
Revenues . . . . . . . . . . . . . . . . $ - 25,051 34,258 37,017
------------ ----------- ----------- ------------
Operating expenses:
General and administrative . . . . . 213,843 414,075 1,312,519 2,414,077
Research and development . . . . . . - 46,655 41,849 316,403
Selling and marketing. . . . . . . . - 24,180 37,033 238,817
Impairment of intellectual property
and equipment (Note 1) . . . . . . . - - 608,061 210,000
------------ ----------- ----------- ------------
213,843 484,910 1,999,462 3,179,297
------------ ----------- ----------- ------------
Loss from operations . . . . . . . . . . (213,843) (459,859) (1,965,204) (3,142,280)
------------ ----------- ----------- ------------
Other income (expense):
Other income . . . . . . . . . . . . . 10,186 - - -
Interest income. . . . . . . . . . . . 1,936 3,418 2,550 7,251
Extinguishment of liabilities
(Note 7) . . . . . . . . . . . . . - - 52,500 -
Equity (loss) income of affiliates
(Note 6) . . . . . . . . . . . . . (4,905) 3,794 (99,922) -
Interest expense . . . . . . . . . . . - (297) (2,889) (38)
------------ ----------- ----------- ------------
7,217 6,915 (47,761) 7,213
------------ ----------- ----------- ------------
Loss from continuing operations. . . . . (206,626) (452,944) (2,012,965) (3,135,067)
------------ ----------- ----------- ------------
Discontinued operations,
income (loss) from
operations of subsidiary (Note 2 (for
quarters ended 9/30) (Note 3 for year
ended 6/30/04) . . . . . . . . . . . . . - (1,920) 454,882 (882,718)
------------ ----------- ----------- ------------
Net loss . . . . . . . . . . . . . . . . $ (206,626) (454,864) (1,558,083) (4,017,785)
============ =========== =========== ============
Basic and diluted loss per share:
Loss from continuing operations. . . $ * (0.01) (0.03) (0.05)
Income (loss) from discontinued
operations . . . . . . . . . . . . . - - 0.01 (0.02)
------------ ----------- ----------- ------------
Net loss per share, basic and diluted. . $ * (0.01) (0.02) (0.07)
============ =========== =========== ============
Weighted average number of
common shares outstanding. . . . . . . 90,059,033 62,404,043 75,116,717 61,647,688
============ =========== =========== ============
__________
* Less than ($0.01) per share.
With respect to the note references in this table relating to the summary
consolidated financial data for the three months ended September 30, 2004 and
2003, see the respective notes to the consolidated financial statements in our
quarterly report on Form 10-QSB for the fiscal quarter ended September 30, 2004,
incorporated by reference into and accompanying this prospectus. With respect
to the note references in this table relating to the summary consolidated
financial data for the years ended June 30, 2004 and 2003, see the respective
notes to the consolidated financial statements in our annual report on Form
10-KSB for our fiscal year ended June 30, 2004, incorporated by reference into
and accompanying this prospectus.
4
RISK FACTORS
When deciding whether or not to purchase our common stock offered by this
prospectus, you should carefully consider the risks described below.
WE MAY NOT BE ABLE TO COMPLETE THE CONTEMPLATED JOINT VENTURE WITH XACT
RESOURCES INTERNATIONAL
On October 1, 2004 we entered into a letter agreement to form a joint
venture with Xact Resources International described under "THE COMPANY." The
forming of the joint venture is contingent upon our ability to make a $1.5
million investment in the joint venture in order to retain a 50% equity interest
in the joint venture. If we cannot secure the additional $1.5 million in
financing we will not be able to participate in the contemplated joint venture.
Pursuant to the letter agreement, we have advanced Xact Resources $225,000.
WE HAVE A HISTORY OF LOSSES
Developing our particle technology and products has been and we expect will
continue to be expensive. We recently have incurred increased operating
expenses without a corresponding increase in revenues. We reported a net loss
of $1,558,083, $4,017,785 and $4,729,072 for our fiscal years ended June 30,
2004, 2003 and 2002, respectively and a net loss of $206,626 for the three-month
period ended September 30, 2004. In addition, we decreased the value of our
intellectual property on our financial statements by $608,061 and $210,000 for
our fiscal years ended June 30, 2004 and 2003, respectively.
WE MAY NOT BE ABLE TO CONTINUE AS A GOING CONCERN
Our independent auditors' report on our financial statements as of June 30,
2004 includes an explanatory paragraph expressing substantial doubt about our
ability to continue as a going concern. As a result of this going concern
modification in our auditors' report on our consolidated financial statements,
we may have a difficult time obtaining significant additional financing. If we
are unable to secure significant additional financing, we may be obligated to
seek protection under the bankruptcy laws and our shareholders may lose their
investment.
WE DO NOT EXPECT TO PAY DIVIDENDS IN THE FORESEEABLE FUTURE
We have never paid cash dividends on our common stock. We do not expect to
pay cash dividends on our common stock at any time in the foreseeable future.
The future payment of dividends directly depends upon our future earnings,
capital requirements, financial requirements and other factors that our board of
directors will consider. Since we do not anticipate paying cash dividends on
our common stock, return on your investment, if any, will depend solely on an
increase, if any, in the market value of our common stock.
THIS OFFERING AND THE SALE OF SECURITIES BY CURRENT STOCKHOLDERS COULD CAUSE
DILUTION OF EXISTING HOLDERS OF OUR COMMON STOCK BY DECREASING THE PRICE OF OUR
COMMON STOCK
The market price of our common stock could be adversely affected by sales
of substantial amounts of common stock in the public market after this offering,
by the perception that those types of sales could occur or by the fact or
perception of events which would have a dilutive effect on the market for our
common stock. As of January 27, 2005, we had 91,259,033 shares of our common
stock outstanding, including shares of our common stock issued as described
under "THE COMPANY." If all of our outstanding options and warrants were
exercised and all of our reserved shares of common stock
5
were issued, we could have up to 179,360,030 shares of common stock outstanding.
Future transactions with other investors could further depress the price of our
common stock because of additional dilution. See "DESCRIPTION OF COMMON STOCK."
OUR ARTICLES OF INCORPORATION MAY LIMIT OUR ABILITY TO SELL ADDITIONAL SHARES OF
OUR COMMON STOCK IN THE FUTURE
We are authorized to issue up to 200,000,000 shares of our common stock.
Overall, we would have a total of 179,360,030 shares of common stock issued and
outstanding if all of our outstanding warrants and options were exercised and
all of our reserved shares of common stock were issued. Unless we amend our
articles of incorporation, our ability to issue additional shares of our common
stock or securities convertible into our common stock is limited.
COMMON STOCK PRICE COULD BE EFFECTED BY THE ABILITY OF HOLDERS OF OUR COMMON
STOCK TO SELL THEIR STOCK
The market price of our common stock will be influenced by the ability of
common stockholders to sell their stock. As of January 27, 2005, approximately
57,401,305 shares of our common stock were freely transferable and constitute
the "float" in the public market for our common stock. If all of our
outstanding options and warrants were exercised and all of our reserved shares
were issued, the "float" for our common stock could increase to a total of
138,263,949 shares. As of January 27, 2005, approximately 33,851,728 shares of
our common stock were "restricted" or "control" securities within the meaning of
Rule 144 under the Securities Act of 1933. These restricted securities cannot
be sold unless they are registered under the Securities Act of 1933, or unless
an exemption from registration is otherwise available, including the exemption
that is contained in Rule 144. If all of our outstanding options and warrants
were exercised and all of our reserved shares were issued, the number of
"restricted" or "control" shares of our common stock could increase to a total
of 41,096,081 shares.
WE COULD ISSUE PREFERRED STOCK THAT COULD ADVERSELY EFFECT THE RIGHTS OF OUR
COMMON STOCKHOLDERS
We are authorized to issue up to 5,000,000 shares of our preferred stock,
$.0001 par value per share. Our articles of incorporation gives our board of
directors the authority to issue preferred stock without approval of our common
stockholders. We may issue preferred stock to finance our operations. We may
authorize the issuance of our preferred stock in one or more series. In
addition, we may set several of the terms of the preferred stock, including:
- dividend and liquidation preferences,
- voting rights,
- conversion privileges,
- redemption terms, and
- other privileges and rights of the shares of each authorized series.
The issuance of large blocks of preferred stock could have a dilutive
effect on our existing shareholders and it can negatively impact our existing
stockholders' liquidation preferences. In addition, while we include preferred
stock in our capitalization to improve our financial flexibility, we could
possibly issue our preferred stock to third parties as a method of discouraging,
delaying or preventing a change in control in our present management.
6
THE RESALE OF OUR COMMON STOCK BY YOU MAY BE LIMITED BECAUSE OF ITS LOW PRICE
WHICH COULD MAKE IT MORE DIFFICULT FOR BROKER/DEALERS TO SELL OUR COMMON STOCK
The Securities Enforcement and Penny Stock Reform Act of 1990 requires
additional disclosure relating to the market for penny stocks in connection with
trades in any stock defined as a penny stock. Regulations enacted by the SEC
generally define a penny stock as an equity security that has a market price of
less than $5.00 per share, subject to some exceptions. Unless an exception
applies, a disclosure schedule explaining the penny stock market and the risks
associated with investing in penny stocks must be delivered before any
transaction in penny stock can occur.
Our common stock is not a reported security and is currently subject to the
Securities and Exchange Commission's "penny stock" rules and it is anticipated
that trading in our common stock will continue to be subject to the penny stock
rules for the foreseeable future.
Until such time as our common stock meets an exception to the penny stock
regulations cited above, trading in our securities is covered by Rule 15g-9
promulgated under the Securities Exchange Act of 1934. Under this rule,
broker/dealers who recommend penny stocks to persons that are not established
customers or accredited investors must make a special determination in writing
for the purchaser that the investment is suitable, and must also obtain the
purchaser's written agreement to a transaction before the sale.
The regulations could limit the ability of broker/dealers to sell our
securities and thus the ability of purchasers of our securities to sell their
securities in the secondary market for so long as our common stock has a market
price of less than $5.00 per share.
OUR REVENUES DEPEND ON OUR ABILITY TO LICENSE COMPANIES TO APPLY OUR PARTICLE
TECHNOLOGY TO PRODUCTS THAT THEY BRING TO THE MARKETPLACE WHICH WE HAVE BEEN
UNABLE TO ACCOMPLISH TO DATE
We do not anticipate generating significant revenues until we are able to
license companies to apply our particle technology to products that are brought
to the marketplace. To date, we have not successfully licensed companies to
apply our particle technology to products that are brought to the marketplace.
Even if we are successful and products utilizing our particle technology are
brought to the marketplace, we may still not generate enough revenue to offset
our operating costs.
We do not have licensing relationships with manufacturers to develop and
market products using our particle technology in place, and if we are unable to
secure these agreements, we believe that we may not become profitable in the
future.
We believe that our long-term profitability and growth depends on entering
into licensing or joint venture relationships with various manufacturers to
develop and market products using the particle technology. We have not entered
into any formal agreements to date, and even if we do enter into agreements in
the future, we cannot assure you that the agreements will be profitable.
CONSUMERS MAY USE ALTERNATIVE TECHNOLOGIES UNLESS WE ESTABLISH A MARKET PRESENCE
WITH OUR PARTICLE TECHNOLOGY
The interconnect market is subject to rapid technology changes. New
products are introduced, old products are enhanced and others become obsolete.
The entire interconnect market may be replaced by a newer form of technology.
To be competitive, we believe that we must develop, market and sell our products
on a timely and cost-effective basis and respond to the ever changing
requirements and demands of our customers, which in turn depends in part on our
capability to upgrade our products and quality control procedures and to adapt
to technological changes and advances in the electronics industry.
7
We cannot assure that we will be successful in selecting, developing, and
marketing new technologies or that compatibility issues with an evolving
generation of electronic components and manufacturing equipment and errors or
flaws in the new technologies will not prevent or delay market acceptance. Any
further delay in bringing our particle technology to the marketplace could cause
prospective customers to use alternative technologies and could result in our
inability to generate sufficient revenues to cover our operating costs.
WE MAY BE UNABLE TO SUCCESSFULLY COMPETE IN THE MARKETPLACE
The interconnect market is highly competitive. Our success will depend in
part on how quickly competitors can design and develop competing products and
technologies. We will compete with suppliers of other interconnect technologies
including Alien Technologies, Inc., Interconnect Technologies and major
electronic technology manufacturing leaders including Philips, Siemens, Infineon
and IBM. We are disadvantaged competing against these competitors in several
different areas, including:
- financial resources;
- technological resources;
- manufacturing capabilities;
- diversity of revenue sources and business opportunities;
- personnel and human resources; and
- research and development capabilities.
Our larger competitors have long term advantages over us in research and
new product development and have a greater ability to withstand periodic
downturns in the interconnect market because they have diverse product lines
that can provide revenue even when there is a downturn in the interconnect
market.
WE CANNOT GUARANTEE THE QUALITY, PERFORMANCE OR RELIABILITY OF OUR PRODUCTS
We have no prior experience in taking technology to the manufacturing or
production stage. We plan to have licensees or co-joint venturers manufacture
products using the particle technology. We expect that the customers of these
products will demand quality, performance and reliability. We cannot assure you
that our future licensees or co-joint venturers will be able to meet the quality
control standards that may be established by equipment manufacturers and other
customers of products utilizing the particle technology.
THERE MAY BE INSUFFICIENT DEMAND FOR OUR PARTICLE TECHNOLOGY
We must convince our potential customers that the particle technology is
technologically sound and can be manufactured efficiently and cost-effectively
before connector manufacturers and electronic equipment manufacturers will be
willing to use our technology. To create this consumer demand, we have to
successfully market and sell our technology. Even after these efforts, our
particle technology may not be viewed by consumers as an improvement over
existing technologies and may not achieve commercial acceptance.
8
WE MAY BE UNABLE TO MEET OUR ONGOING NEEDS FOR ADDITIONAL CAPITAL
We cannot accurately predict how much funding we will need to implement our
strategic business plan or to continue operations. Our future capital
requirements, the likelihood that we can obtain money and the terms of any
financing will be influenced by many different factors, including:
- our revenues,
- the status of competing products in the marketplace,
- our performance in the marketplace,
- our overall financial condition,
- our business prospects,
- the perception of our growth potential by the public, including
potential lenders,
- our ability to enter into joint venture or licensing relationships to
achieve a market presence and
- our progress in developing, marketing and selling the particle
technology.
If we cannot obtain adequate financing or if the terms on which we are able
to acquire financing are unfavorable, our business and financial condition could
be negatively affected. We may have to delay, scale back or eliminate some or
all of our development and marketing programs, if any. We may also have to go
to third parties to seek financing, and in exchange, we may have to give up
rights to some of our technologies, patents, patent applications, potential
products or other assets.
WE MAY BE UNABLE TO HIRE AND RETAIN KEY PERSONNEL
Our future success depends on our ability to attract qualified technical
personnel capable of working with our technology. We may be unable to attract
these necessary personnel. If we fail to attract or retain skilled employees,
or if a key employee fails to perform in his or her current position, we may be
unable to bring our particle technology to the marketplace and to generate
sufficient revenues to offset our operating costs.
WE MAY BE UNABLE TO OBTAIN AND RETAIN APPROPRIATE PATENT, COPYRIGHT AND
TRADEMARK PROTECTION OF OUR PRODUCTS
We protect our intellectual property rights through patents, trademarks,
trade names, trade secrets and a variety of other measures. However, these
measures may be inadequate to protect our intellectual property or other
proprietary information.
- TRADE SECRETS MAY BECOME KNOWN BY THIRD PARTIES. Our trade secrets or
proprietary technology may become known or be independently developed by
competitors.
- RIGHTS TO PATENTS AND TRADE SECRETS MAY BE INVALIDATED. Disputes may
arise with third parties over the ownership of our intellectual property rights.
Our patents may be invalidated, circumvented or challenged, and the rights
granted under those patents that provide us with a competitive advantage may be
nullified.
9
- PROBLEMS WITH FUTURE PATENT APPLICATIONS. Our pending or future
patent applications may not be approved, or the scope of the granted patent may
be less than the coverage sought.
- INFRINGEMENT CLAIMS BY THIRD PARTIES. Infringement, invalidity, right
to use or ownership claims by third parties or claims for indemnification may be
asserted by third parties in the future. If any claims or actions are asserted
against us, we can attempt to obtain a license for that third party's
intellectual property rights. However, the third party may not provide a
license under reasonable terms, or may not provide us with a license at all.
- THIRD PARTIES MAY DEVELOP SIMILAR PRODUCTS. Competitors may develop
similar products, duplicate our products or may design around the patents that
are owned by us.
- LAWS IN OTHER COUNTRIES MAY INSUFFICIENTLY PROTECT INTELLECTUAL
PROPERTY RIGHTS ABROAD. Foreign intellectual property laws may not adequately
protect our intellectual property rights abroad. Our failure to protect these
rights could adversely affect our business and financial condition.
- LITIGATION MAY BE REQUIRED TO PROTECT INTELLECTUAL PROPERTY RIGHTS.
Litigation may be necessary to protect our intellectual property rights and
trade secrets, to determine the validity of and scope of the rights of third
parties or to defend against claims of infringement or invalidity by third
parties. This litigation could be expensive, would divert resources and
management's time from our sales and marketing efforts, and could have a
materially adverse effect on our business, financial condition and results of
operations and on our ability to enter into joint ventures or partnerships with
others.
LICENSE RIGHTS TO PARTICLE TECHNOLOGY MAY LIMIT OUR ABILITY TO COMPETE
Before we acquired the patents, patent applications and licenses from the
original owners of the particle technology, the inventor of the particle
technology granted five companies exclusive and non-exclusive licenses to use
the patents and patent applications relating to the particle technology. At
this time, only two of the original five licensees are using our technology and
none of these licenses relate to either smart card or smart label technology. A
non-exclusive, two year license was also granted to the inventor of the particle
technology in October 2002 in connection with the settlement of certain
litigation with the inventor. These licenses restrict us as follows:
- EXCLUSIVE LICENSES PREVENT US FROM COMPETING AGAINST THE EXCLUSIVE
LICENSES. We cannot compete in the fields in which exclusive licenses have been
granted. An exclusive license was granted in the field of sockets for use in
the automated handling and testing of integrated circuits, a type of
semiconductor in which a number of transistors and other elements are combined
to form a more complicated circuit.
- NON-EXCLUSIVE LICENSES ALLOW LICENSEES TO COMPETE AGAINST US IN
CERTAIN AREAS. The licensees with non-exclusive licenses can compete directly
with us or our other future licensees. Non-exclusive licenses have been granted
to use the particle technology for electrically conductive components,
laminate-based and metal-based products and semiconductor products. If the
present licensees decide to compete with us or our future licensees, this
competition could adversely affect our business.
10
THE COMPANY
GENERAL
We were incorporated on June 22, 1996 as a Nevada corporation. Our
corporate offices are located at 370 - 17th Street, Suite 3640, Denver, Colorado
80202, and our telephone number is (303) 592-1010. We maintain a website at
www.nanopierce.com, which is not incorporated into and is not a part of this
------------------
prospectus. This prospectus is accompanied by a copy of our annual report on
Form 10-KSB for our fiscal year ended June 30, 2004 and our quarterly report on
Form 10-QSB for the fiscal quarter ended September 30, 2004.
On February 26, 1998, we acquired the intellectual property rights related
to our patented Particle Interconnect Technology (the "particle technology")
from Particle Interconnect Corporation, a Colorado corporation, a wholly-owned
subsidiary of Intercell Corporation (now known as Intercell International
Corporation), a Nevada corporation that was once our affiliate as a result of
the acquisition. We acquired the particle technology to pursue a more focused,
strategic application and development of the particle technology.
We have designated and are commercializing our particle technology as the
Nanopierce Connection System ("NCS(TM) "). NCS(TM) is an alternative method of
providing temporary or permanent electrical connections between different
flexible, rigid, metallic and non-metallic surfaces. Through the use of our
particle technology, we can also attach semi-conductors directly to various
surfaces. We have trademarked this process as WaferPierce.(TM)
On January 12, 2004, we entered into a placement agent agreement with
Charleston Capital Corp. (now known as Clayton Dunning & Company, Inc.) in
connection with a proposed sale of our securities to a number of "accredited
investors" (as defined in the Securities Act of 1933, as amended), in a private
placement transaction exempt from registration pursuant to Section 4(2) of the
Securities Act of 1933 and Rule 506 of Regulation D promulgated under the
Securities Act of 1933.
CURRENT DEVELOPMENTS
We do not currently plan to manufacture or develop products that utilize
our particle technology and we have no prior experience in taking technology to
the manufacturing or production stage. We expect to generate revenue by
licensing companies to apply our particle technology to products that are
brought to the marketplace by those licensees or by entering into joint ventures
with companies that manufacture products using the particle technology. To
date, we have not successfully licensed companies to manufacture, develop and
market products using our particle technology, and we do not currently have
licensing relationships in place.
On October 1, 2004, we signed a letter agreement with Xact Resources
International, Inc. The letter agreement provides for the development of a
joint venture between us and Xact Resources. The purpose of the joint venture
would be to produce, market and sell YBG-2000, a biotech yeast beta glucan
product which has been developed by Xact Resources. YBG-2000 is a natural beta
glucan immune system feed supplement refined from bakers yeast. It is used to
replace antibiotic fast growth additives which are currently used by producers
of feeds for the livestock, poultry and shrimp industries. At this time, we
have not formally entered into the joint venture. Our participation in the
joint venture depends on our ability to contribute cash in the amount of $1.5
million and we cannot assure you that we will be successful in raising the
necessary capital. Pursuant the letter agreement, we have advanced $225,000 to
Xact Resources to date. See "RISK FACTORS."
11
During the fiscal year ended June 30, 2004, we minimized our operations to
conserve funds. After the completion of the financing described below under
"PLAN OF DISTRIBUTION-Private Placement," we revised our business strategy and
intend to use the funds received or to be received from such sale to support
minimal operations while we investigate potential acquisition targets. In
addition, we dissolved a wholly-owned subsidiary (NanoPierce Card), terminated
operations of a wholly-owned subsidiary (NanoPierce Connection), sold a majority
interest in a subsidiary (ExypnoTech), entered into a joint venture (Scimaxx
Solutions) and formed a new wholly-owned subsidiary (ExypnoTech, LLC), each as
described below.
1. NANOPIERCE CARD TECHNOLOGIES, GMBH. "NanoPierce Card" was established
in January 2000 and was located in Hohenbrunn, Germany. NanoPierce Card was
responsible for the marketing of our technology, services and products on an
international basis. On April 1, 2003, NanoPierce Card filed for insolvency
with the Courts of Munich, Germany. The insolvency was necessary in order to
comply with specific German legal requirements. In conjunction, with the
insolvency filing, management decided in April 2003 to discontinue operations at
NanoPierce Card and to liquidate NanoPierce Card, through a self-liquidation.
We completed the plan of self-liquidation and the German court legally dissolved
NanoPierce Card on June 8, 2004.
2. NANOPIERCE CONNECTION SYSTEMS, INC. "Nanopierce Connection," a Nevada
corporation, was located in Colorado Springs, Colorado, USA. Beginning business
in January 2002, NanoPierce Connection was the center for research and
development activities. In September 2003, we entered into a joint venture with
Scimaxx, LLC in order to further the marketing of the services previously
offered by NanoPierce Connection. In return for a 50% ownership interest in the
newly created joint venture (Scimaxx Solutions described below), we contributed
a license to utilize its technology and the facilities and equipment of
NanoPierce Connections. We have no ongoing responsibilities to make any cash
contributions to the joint venture.
3. EXYPNOTECH, GMBH. "Exypnotech" was organized in February 2002.
ExypnoTech produces inlay components used in the manufacturing of, among other
things, smart labels (often referred to as radio frequency identification tags
or "RFID"). ExypnoTech, in addition to the inlay components, plans to
manufacture and sell other types of RFID components. In December 2003
ExypnoTech sold a controlling 51% interest in ExypnoTech to TagStar Systems,
GmbH for $98,000 in cash. As a result of this sale, we do not have a
controlling interest in ExypnoTech and we are only entitled to 49% of the net
income, if any, generated by ExypnoTech. ExypnoTech, if able, will pay
dividends on an annual basis. We are entitled to 49% of the dividends, if any,
paid as a result of any future profits of ExypnoTech. The sale of the
controlling interest in ExypnoTech decreased our revenues from ExypnoTech.
4. SCIMAXX SOLUTIONS, LLC. On September 15, 2003, we entered into a
joint venture with Scimaxx, LLC (Dr. Neuhaus, one of our directors is a part
owner of Scimaxx, LLC). The purpose of the joint venture is to provide the
electronics industry with technical solutions to manufacturing problems based on
the need for electrical connectivity. We received a 50% interest in the joint
venture ("Scimaxx Solutions") in exchange for a contribution of the equipment
owned by NanoPierce Connection. We also granted Scimaxx Solutions a ten-year,
non-exclusive, non-royalty bearing worldwide license to use our intellectual
property. Scimaxx, LLC is to invest $50,000 cash, of which $22,900 has been
received as of September 30, 2004. The terms of the joint venture provide for
us to share in 50% of joint venture net profits, if any. We are to share in 50%
of joint venture net losses beyond the first $50,000. We have a 49% voting
interest in the joint venture.
12
5. EXPNOTECH, LLC. On June 18, 2004, we organized ExypnoTech, LLC as a
wholly-owned subsidiary to market, primarily in the United States of America,
the RFID components manufactured by ExypnoTech, GmbH.
We recognized $34,258 of revenues from continuing operations during the
fiscal year ended June 30, 2004 compared to $37,017 in the fiscal year ended
June 30, 2003. Revenues recognized by discontinued operations were $0 during
the fiscal year ended June 30, 2004 and $128,947 for the fiscal year ended June
30, 2003. The revenue generated from continuing operations was from the sale of
inlays by ExypnoTech, $28,449 through December 2003, and $5,809 through services
provided by us. The results of our operations are described in more detail in
our annual report on Form 10-KSB for our fiscal year ended June 30, 2004 and our
quarterly report on Form 10-QSB for the fiscal quarter ended September 30, 2004,
which accompany this prospectus.
USE OF PROCEEDS
The shares of our common stock offered by this prospectus are being
registered for the account of the selling stockholders named in this prospectus.
Therefore, any proceeds from the sale of our common stock will be received by
the related selling stockholders for their own account, and we will not receive
any proceeds from the sale of our common stock offered by this prospectus.
With respect to the shares of our common stock offered by this prospectus,
we previously received $2,000,000 from the sale of units described in "THE
COMPANY." We used a portion of the proceeds from the sale of the units to pay
in full several outstanding promissory notes, the interest rates, principal
amounts and maturity dates of which are set forth in the following table.
LENDER INTEREST RATE PRINCIPAL AMOUNT MATURITY DATE
(PER ANNUM)
Intercell International 7% $ 35,000 September 2004
Corporation
Intercell International 7% $ 100,000 November 2004
Corporation
Paul H. Metzinger, 7% $ 10,000 December 2003
(President, Chief Executive
Officer and director)
Paul H. Metzinger, 7% $ 30,000 September 2004
(President, Chief Executive
Officer and director)
The remainder of the proceeds from the sale of the units were used for general
working capital purposes. Assuming that all of the warrants that we issued to
the selling stockholders described in "THE COMPANY" were exercised, we expect to
receive an additional $8,455,000, substantially all of which we expect to use
for general working capital purposes, including strategic acquisitions of
technology or other businesses. However, no assurance can be given that any of
these warrants will be exercised. We will incur all of the costs associated
with the registration of the shares of our common stock offered by this
prospectus other than underwriting discounts and selling commissions, if any.
See "PLAN OF DISTRIBUTION."
13
DETERMINATION OF OFFERING PRICE
The selling stockholders may sell all or a portion of their shares of our
stock in the over-the-counter market at prices prevailing at the time of sale,
or related to the market price at the time of sale, or at other negotiated
prices. See "PLAN OF DISTRIBUTION."
SELLING STOCKHOLDERS
BACKGROUND
We are registering the shares of our common stock offered for resale by
this prospectus in order to satisfy our obligations to the selling stockholders
named below under "-Selling Stockholders Table." In January of 2004, we sold
20,000,000 units for a total of $2,000,000 to the first ten selling stockholders
named below under "-Selling Stockholders Table" (all of whom are accredited
investors) in a private placement transaction exempt from registration under
Section 4(2) of the Securities Act of 1933 and Regulation D promulgated under
the Securities Act of 1933. Each unit consists of:
- one share of our common stock;
- a warrant to purchase one share of our common stock at an
exercise price of $0.10 per share (the "$0.10 investor
warrants"); and
- a warrant to purchase two shares of our common stock at an
exercise price of $0.25 per share (the "$0.25 investor
warrants").
On November 16, 2004, we voluntarily reduced the exercise price of the
$0.25 investor warrants to $0.15 per share (the "$0.15 investor warrants").
These warrants will expire on January 20, 2009 unless exercised earlier.
Pursuant to the securities purchase agreement between us and the first ten
selling stockholders named below under "-Selling Stockholders Table," we are
obligated to register under the Securities Act of 1933, all the shares of our
common stock purchased by each of these selling stockholders, as well as the
shares of our common stock that will be held by each of these stockholders
assuming these stockholders exercise all of the $0.10 investor warrants and
$0.15 investor warrants. We are obligated to keep the registration statement of
which this prospectus forms a part effective until the earliest of the date on
which the warrants have all been exercised and January 20, 2009.
We are registering the remaining shares of our common stock for Clayton
Dunning & Company, Inc. (f/k/a Charleston Capital Corp.), Chris Messalas, Jason
Lyons and GRQ Consultants, Inc. as a result of so-called "piggy-back"
registration rights, which means that, because we are required by the securities
purchase agreement to file the registration statement of which this prospectus
forms a part, holders of "piggy-back" registration rights must also be given the
opportunity to have their shares of our common stock registered in the
registration statement of which this prospectus forms a part.
SELLING STOCKHOLDERS TABLE
The shares of our common stock offered by this prospectus are being sold
for the account of the selling stockholders identified in the following table.
Except for the private placement transaction described in the previous section
and under "PLAN OF DISTRIBUTION," for the last three years, none of the selling
stockholders have held any position, office or have other material relationship
with us, our
14
predecessors or our affiliates. The information in the following table and
footnotes is based solely on information furnished to us by the selling
stockholders on or prior to the date of this prospectus. However, any or all of
the common stock listed below may be offered for sale with this prospectus by
the selling stockholders from time to time. Accordingly, no estimate can be
given as to the amount of our common stock that will be held by the selling
stockholders upon consummation of any sales. In addition, the selling
stockholders listed in the table below may have acquired, sold or transferred,
in transactions exempt from the registration requirements of the Securities Act,
some or all of their securities since the date this information was last
provided to us. The information in the following table for each selling
stockholder includes:
(a) the name and address of the selling stockholder,
(b) the number of shares of our common stock currently beneficially
owned by the selling stockholder and the percentage that those shares of
our common stock represent of all of our outstanding common stock as of
January 27, 2005 (on a fully-diluted basis),
(c) the number of shares of our common stock offered by the selling
stockholder, and
(d) the amount and, if 1% or more, the percentage of shares of our
common stock that will be beneficially owned by the selling stockholder
after completion of the offering, assuming the sale of all of the shares of
our common stock as shown in (d) above.
Except as indicated in the footnotes to this table, the persons named in the
table have sole voting and investment power with respect to all shares of our
common stock shown as beneficially owned by them. Each selling stockholder that
is a broker-dealer or is affiliated with a broker-dealer, including Clayton
Dunning & Company, Inc. (f/k/a Charleston Capital Corp.), Jason Lyons, Chris
Messalas and related persons (a) has represented to us that it purchased the
securities to be resold pursuant to this prospectus in the ordinary course of
business and, at the time of the purchase of such securities, had no agreements
or understandings, directly or indirectly, with any person to distribute such
securities; and (b) may not sell, transfer, assign, pledge or hypothecate or
otherwise dispose of any of the shares of common stock listed below for a period
of 180 days immediately following the later of the effective date of the
registration statement of which this prospectus forms a part and the date of the
first sale of shares of our common stock pursuant to this prospectus in
accordance with Rule 2710(g) of the conduct rules of the National Association of
Securities Dealers, Inc. The names of the selling stockholders and the number
of shares of common stock subject to the 180-day restriction described in the
previous sentence are set forth below under "PLAN OF DISTRIBUTION-Selling
Stockholders." The selling stockholders and any brokers, dealers, agents or
underwriters that participate in the distribution of the common stock may be,
and Clayton Dunning & Company, Inc. (f/k/a Charleston Capital Corp.) will be,
deemed to be "underwriters" within the meaning of the Securities Act of 1933.
(A) (B) (C) (D)
AMOUNT OF COMMON AMOUNT OF
STOCK/PERCENTAGE OF COMMON STOCK
NAME AND ADDRESS OF OUR COMMON STOCK AMOUNT OF COMMON OWNED AFTER
SELLING STOCKHOLDER OWNED BEFORE OFFERING STOCK OFFERED OFFERING(1)
M/S Family Foundation(2)
242 4th Street
Lakewood, NJ 08701 1,500,000(3a) / 0.80% 1,500,000(3a) 0
Platinum Partners Value Arbitrage
Fund LP(4)
152 West 57th Street
New York, NY 10019 21,000,000(3a) / 11.71% 21,000,000(3a) 0
15
Peekskill, LLC(5)
152 West 57th Street
New York, NY 10019 9,000,000(3a) /5.02% 9,000,000(3a) 0
Laura Huberfeld Naomi Bodner
Partnership(6)
15 Manor Lane
Lawrence, NY 11559 3,000,000(3a) / 1.67% 3,000,000(3a) 0
Omega Capital Small Cap Fund, LTD(7)
1243 48th Street
Brooklyn, NY 11219 15,400,000(3b) / 8.59% 15,400,000(3b) 0
Colbart Birnet LP(8)
10 West 40th Street
22nd Floor
New York, NY 10016 1,000,000(3c) / 0.56% 1,000,000(3c) 0
Goldstrand Investments(9)
1040 1st Ave., Suite 190
New York, NY 10022 3,400,000(3c) / 1.90% 3,400,000(3c) 0
Marketwise Trading, Inc. (10)
21 Crestview Terrace
Monsey, NY 10952 4,000,000(3c) / 2.24% 4,000,000(3c) 0
Jules Nordlicht
225 West Beach Street
Long Beach, NY 11561 3,000,000(3a) / 1.67% 3,000,000(3a) 0
Ellis International (11)
27 Old Gloncester Street
London Wein 3xx 3,000,000(3a) / 1.67% 3,000,000(3a) 0
Clayton Dunning & Company, Inc. (12)
31st Floor, 40 Wall Street
New York, NY 10005. 210,000(13) / 0.12% 210,000(13) 0
Jason Lyons(14)
7239 San Salvador Drive
Boca Raton, FL 33433 1,000,000(15) / 0.56% 1,000,000(15) 0
GRQ Consultants, Inc. (16)
3290 NW 53rd Circle
Boca Raton, Florida 33496 1,000,000 (17) / 0.56% 1,000,000(17) 0
Chris Messalas
20 Carlton Place
Staten Island, NY 10301 390,000(13) / 0.22% 390,000(13) 0
Arizcan Properties, Ltd. (18)
77 South Adams, Ste. 906
Denver, CO 80219 15,700,000(19) / 8.75% 15,700,000(19) 0
(1) Assumes that all of the shares of our common stock relating to 20,000,000
units that we previously sold to a number of accredited investors as described
under "PLAN OF DISTRIBUTION-Private Placement," including those issued upon the
exercise of warrants, are sold by the selling stockholders. There is no
assurance that the selling stockholders will exercise all or any of their
warrants or that they will sell any or all of their shares offered by this
prospectus.
(2) Shoshana Englander has voting and dispositive power over the shares of
common stock being offered.
16
(3a) Assumes the exercise of all of the $0.15 investor warrants purchased by the
named selling stockholder as part of the 20,000,000 units we sold to a number of
accredited investors as described under "PLAN OF DISTRIBUTION-Private
Placement." Assumes all the $0.10 investor warrants purchased by the named
selling stockholder as part of the 20,000,000 units we sold to a number of
accredited investors as described under "PLAN OF DISTRIBUTION-Private Placement"
were not exercised by such selling stockholder as a result of the grant of the
option to exercise the $0.10 investor warrants by each named selling stockholder
to Arizcan Properties, Ltd. See footnote 19 to this table.
(3b) Assumes the exercise of all of the $0.15 investor warrants and 2,200,000 of
the $0.10 investor warrants purchased by the named selling stockholder as part
of the 20,000,000 units we sold to a number of accredited investors as described
under "PLAN OF DISTRIBUTION-Private Placement." Assumes the remaining 2,200,000
$0.10 investor warrants purchased by the named selling stockholder were not
exercised by such selling stockholder as a result of the grant of the option to
exercise the $0.10 investor warrants by such selling stockholder to Arizcan
Properties, Ltd. See footnote 19 to this table.
(3c) Assumes the exercise of all of the $0.10 investor warrants and $0.15
investor warrants purchased by the named selling stockholder as part of the
20,000,000 units we sold to a number of accredited investors as described under
"PLAN OF DISTRIBUTION-Private Placement."
(4) Mark Nordlict is the general partner of the listed selling stockholder and
has voting and dispositive power over the shares of common stock being offered.
(5) Mark Nordlict is the general partner of the listed selling stockholder and
has voting and dispositive power over the shares of common stock being offered.
(6) Laura Huberfeld, partner, has voting and dispositive power over the shares
of common stock being offered.
(7) Herman Segal, President, has voting and dispositive power over the shares of
common stock being offered.
(8) Ezra Birnbaum is the general partner of the listed selling stockholder and
has voting and dispositive power over the shares of common stock being offered.
The selling stockholder is the general partner of the owner of Pond Equities, a
registered broker-dealer.
(9) Seth Fireman has voting and dispositive power of the shares of common stock
being offered.
(10) Rachel L. Gershan, President of the selling stockholder, has voting and
dispositive power over the shares of common stock being offered.
(11) Wilhelm Ungar has voting and dispositive power over the shares of common
stock being offered.
(12) Robert O. Lau has voting and dispositive power over the shares of common
stock being offered. Clayton Dunning & Company, Inc. (f/k/a Charleston Capital
Corp.) is a registered broker-dealer.
(13) Assumes that the warrants to purchase 600,000 shares of our common stock
issued to Charleston Capital Corp. (now known as Clayton Dunning & Company,
Inc.) (390,000 of which were transferred to Chris Messalas, a registered
representative of Clayton Dunning & Company, Inc.) were exercised.
(14) Jason Lyons is a registered representative of Sunrise Securities Corp., a
registered broker-dealer.
(15) Assumes that the warrants to purchase 1,000,000 shares of our common stock
issued to Jason Lyons were exercised.
(16) Barry Honig has sole voting and dispositive power over the shares of common
stock being offered.
(17) Assumes that the warrants to purchase 1,000,000 shares of our common stock
issued to GRQ Consultants, Inc. were exercised.
(18) Harold D. Mitchell, President of the selling stockholder, has sole voting
and dispositive power over the shares of common stock being offered.
(19) As disclosed in footnotes 3(a), 3(b) and 3(c) to this table, the named
selling stockholders granted an option to Arizcan Properties, Ltd. to exercise
$0.10 investor warrants to purchase 15,700,000 shares of our common stock
initially issued as part of the 20,000,000 units that we previously sold to a
number of accredited investors as described under "PLAN OF DISTRIBUTION-Private
Placement." Assumes the exercise of all $0.10 investor warrants granted to
Arizcan Properties, Ltd.
DESCRIPTION OF COMMON STOCK
Our authorized capital stock consists of 200,000,000 shares of common
stock, $.0001 par value per share, and 5,000,000 shares of preferred stock,
$.0001 par value per share. As of January 27, 2005 we had 91,259,033 shares of
common stock and no shares of preferred stock issued and outstanding. We have
outstanding warrants and options which, if exercised, would total 76,181,877
shares of common
17
stock. We have also reserved 11,919,120 shares of our common stock in
connection with our ongoing litigation with Harvest Court, LLC described in our
annual report on Form 10-KSB for the year ended June 30, 2004. Overall, we
would have a total of 179,360,030 shares of common stock issued and outstanding
if all of our outstanding warrants and options were exercised and all of our
reserved shares of common stock were issued.
COMMON STOCK
Each share of our common stock is entitled to one vote on each matter
submitted to a vote of the stockholders and is equal to each other share of our
common stock with respect to voting, liquidation and dividend rights. Holders
of our common stock are entitled to receive the dividends, if any, as may be
declared by our board of directors out of assets legally available therefor and
to receive net assets in liquidation after payment of all amounts due to
creditors and any liquidation preference due to preferred stockholders. Holders
of our common stock have no conversion rights and are not entitled to any
preemptive or subscription rights. Our common stock is not subject to
redemption or any further calls or assessments. Our common stock does not have
cumulative voting rights in the election of directors.
The transfer agent for our common stock is Corporate Stock Transfer, Inc.,
3200 South Cherry Creek Drive, Suite 430, Denver, Colorado 80209.
DIVIDEND POLICY
While there currently are no restrictions prohibiting us from paying
dividends to our stockholders, we have not paid any cash dividends on our common
stock in the past and we do not anticipate paying any dividends in the
foreseeable future. Earnings, if any, are expected to be retained to fund our
future operations. There can be no assurance that we will pay dividends at any
time in the future.
TRADING OF OUR COMMON STOCK
Our common stock presently is quoted on the over-the-counter bulletin board
maintained by the National Association of Securities Dealers, Inc. under the
symbol "NPCT." Our common stock also is traded on the Frankfurt Stock Exchange
and on the Hamburg Stock Exchange under the symbol "NPI." The average of the
closing bid and asked prices for our common stock was $0.16 per share (rounded
to the nearest penny) on January 27, 2005.
PLAN OF DISTRIBUTION
PRIVATE PLACEMENT
On January 12, 2004, we entered into a placement agent agreement with
Charleston Capital Corp. (now known as Clayton Dunning & Company, Inc.) in
connection with a proposed sale of our securities to a number of "accredited
investors" (as defined in the Securities Act of 1933, as amended), in a private
placement transaction exempt from registration pursuant to Section 4(2) of the
Securities Act of 1933 and Rule 506 of Regulation D promulgated under the
Securities Act of 1933.
In January of 2004, we sold 20,000,000 units for a total of $2,000,000 to a
limited number of accredited investors in a private placement transaction exempt
from registration under Section 4(2) of the Securities Act of 1933 and
Regulation D promulgated under the Securities Act of 1933. Each unit consists
of:
18
- one share of our common stock;
- a warrant to purchase one share of our common stock at an
exercise price of $0.10 per share (the "$0.10 investor
warrants"); and
- a warrant to purchase two shares of our common stock at an
exercise price of $0.25 per share (the "$0.25 investor
warrants").
On November 16, 2004, we voluntarily reduced the exercise price of the $0.25
investor warrants to $0.15 per share (the "$0.15 investor warrants"). These
warrants will expire on January 20, 2009 unless exercised earlier. In
connection with the private placement, we compensated Charleston Capital Corp.
(now known as Clayton Dunning & Company, Inc.) as follows:
- a fee equal to 3% of the gross proceeds ($60,000) received by us
as a result of the issuance of the units described above;
- warrants to purchase 600,000 shares of our common stock at an
exercise price of $0.10 per share that expire on January 20,
2009, unless exercised earlier;
- a right of first refusal on any financing that we enter into for
a period of one year from the date of the effectiveness of the
registration statement of which this prospectus forms a part
(which is considered by the National Association of Securities
Dealers, Inc. to be an item of "underwriting compensation" valued
at 1% of the offering proceeds).
We were also required to compensate Clayton Dunning & Company 3% of the
gross proceeds from exercise of warrants issued as part of the units described
above and warrants equal to 3% of number of shares purchased upon exercise of
warrants issued as part of the units described above. Clayton Dunning & Company
has since waived this warrant solicitation fee and the right to receive the
additional warrants.
We have been advised that Clayton Dunning & Company, Inc. (f/k/a Charleston
Capital Corp.) transferred 390,000 of the warrants described above as
compensation to Chris Messalas, one of Clayton Dunning & Company's registered
representatives.
Jason Lyons, not affiliated with us, received a fee equal to 4.9999% of the
gross proceeds received by us from the sale of the units for introducing us to
Charleston Capital Corp. (now known as Clayton Dunning & Company, Inc.) and the
purchasers and for consulting work done on our behalf. We also issued to Jason
Lyons warrants to purchase 4.9999% of the shares of our common stock issued with
the units (1,000,000 shares of our common stock). The warrants have an exercise
price of $0.10 per share and expire on January 20, 2009 unless exercised
earlier. We are also required to issue to Jason Lyons additional warrants to
purchase a total of 4.9999% of the total number of shares issued as a result of
the exercise of the $0.10 investor warrants described above. If all of the
$0.10 investor warrants are exercised, we will be required to issue to Jason
Lyons additional warrants to purchase 1,000,000 shares of our common stock. All
of the additional warrants will also have an exercise price of $0.10 per share
and expire on January 20, 2009 unless exercised earlier.
GRQ Consultants, Inc., also unaffiliated with us, received a fee equal to
5% of the gross proceeds received by us from the sale of the units for
introducing us to Jason Lyons and for consulting work done on our behalf. We
also issued to GRQ Consultants warrants to purchase 5% of the shares of our
common
19
stock issued with the units (1,000,000 shares of our common stock). We are also
required to issue to GRQ Consultants additional warrants to purchase a total of
5% of the total number of shares issued as a result of the exercise of the $0.10
investor warrants described above. If all of the $0.10 investor warrants are
exercised, we will be required to issue to GRQ Consultants additional warrants
to purchase 1,000,000 shares of our common stock. All of the additional
warrants will also have an exercise price of $0.10 per share and expire on
January 20, 2009 unless exercised earlier.
If all of the $0.10 warrants and $0.15 warrants issued or to be issued in
connection with the private placement transaction were exercised, we expect to
receive an additional $8,455,000. However, no assurance can be given that any
of these warrants will be exercised. We will not receive any proceeds from the
sale of our common stock by the selling stockholders.
SELLING STOCKHOLDERS
Clayton Dunning & Company, Inc. (f/k/a Charleston Capital Corp.) has no
arrangements with us to distribute any of the shares offered by this prospectus.
The selling stockholders may, from time to time, use this prospectus to sell all
or a portion of the shares of our common stock offered by this prospectus.
These sales and transfers of our common stock may be effected from time to time
in one or more transactions on the over-the-counter bulletin board, in the
over-the-counter market, in negotiated transactions or otherwise, at a fixed
price or prices, which may be changed, at market prices prevailing at the time
of sale, at negotiated prices, or without consideration, or by any other legally
available means.
These transfers or sales may occur directly or by or through brokers,
dealers, agents or underwriters, who may receive compensation in the form of
underwriting discounts, concessions or commissions from the selling holders
and/or from purchasers of the common stock for whom they may act as agent. Any
or all of the shares of common stock may be sold or transferred from time to
time by means of:
- a block trade in which the broker or dealer so engaged will
attempt to sell the common stock as agent but may position and
resell a portion of the block as principal to facilitate the
transaction;
- purchases by a broker or dealer as principal and resale by that
broker or dealer for its account based on this prospectus;
- ordinary brokerage transactions and transactions in which the
broker solicits purchasers;
- the writing of options on the common stock;
- pledges as collateral to secure loans, credit or other financing
arrangements and any subsequent foreclosure, if any, under those
arrangements;
- gifts, donations and contributions; and
- any other legally available means.
To the extent required by the Securities Act of 1933, the number of shares
of common stock to be sold or transferred, the purchase price, the name of any
agent, broker, dealer or underwriter and any applicable discounts or commissions
and any other required information with respect to a particular offer will be
shown in an accompanying prospectus supplement or post-effective amendment.
20
In the event of the transfer by any selling stockholder of shares of our
common stock offered by this prospectus to any pledge, donee or other
transferee, we will supplement or amend this prospectus (as required by the
Securities Act of 1933) and the registration statement of which this prospectus
forms a part in order to have the pledge, donee or other transferee included as
a selling stockholder.
We have agreed to keep this prospectus effective until the earlier of the
date on which no warrants that we previously issued or are required to issue to
the selling stockholders described above under "SELLING STOCKHOLDERS-Background"
to purchase shares of our common stock remain unexercised by the selling
stockholders and January 20, 2009.
If necessary to comply with state securities laws, the common stock will be
sold only through registered or licensed brokers or dealers. In addition, the
common stock may not be sold unless it has been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.
The selling stockholders and any brokers, dealers, agents or underwriters
that participate in the distribution of the common stock may be, and Clayton
Dunning & Company, Inc. (f/k/a Charleston Capital Corp.) will be, deemed to be
"underwriters" within the meaning of the Securities Act of 1933, in which event
any discounts, concessions and commissions received by those brokers, dealers,
agents or underwriters and any profit on the resale of the common stock
purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act of 1933.
The selling stockholders that are broker-dealers or affiliates of
broker-dealers may not sell, transfer, assign, pledge or hypothecate or
otherwise dispose of any of the shares of common stock offered by this
prospectus for a period of 180 days immediately following the later of the
effective date of the registration statement of which this prospectus forms a
part and the date of the first sale of shares of our common stock pursuant to
this prospectus in accordance with Rule 2710(g) of the conduct rules of the
National Association of Securities Dealers, Inc. The names of the selling
stockholders and the number of shares of common stock subject to the 180-day
restriction described in the previous sentence include the following:
Name of selling stockholder Number of shares of our common
stock restricted from sale pursuant to
Rule 2710(g)
Clayton Dunning & Company, Inc. 210,000
(f/k/a Charleston Capital Corp.)
Chris Massalas 390,000
Jason Lyons 1,000,000
No underwriter, broker, dealer or agent has been engaged by us or, to our
knowledge, any of the selling stockholders, in connection with the distribution
of the common stock.
We and the selling stockholders will be subject to the applicable
provisions of the Securities Exchange Act of 1934 and the rules and regulations
under it, including, without limitation, Rule 10b-5 and, insofar as the selling
stockholders are distributors and we, under certain circumstances, may be a
distribution participant, under Regulation M.
The anti-manipulation provisions of Regulation M under the Securities
Exchange Act of 1934 will apply to purchases and sales of shares of our common
stock by the selling stockholders, and there are
21
restrictions on market-making activities by persons engaged in the distribution
of the shares of our common stock. Under Regulation M, a selling stockholder or
its agents may not bid for, purchase, or attempt to induce any person to bid for
or purchase, shares of our common stock while they are distributing shares of
our common stock covered by this prospectus. Accordingly, the selling
stockholders are not permitted to cover short sales by purchasing shares of our
common stock while the distribution is taking place.
Any common stock covered by this prospectus which also qualify for sale
based on Rule 144 under the Securities Act of 1933 may be sold under Rule 144
rather than based on this prospectus. There is no assurance that the selling
stockholders identified in this prospectus will sell any or all of the common
stock. The selling stockholders may transfer, devise or gift common stock by
other means not described in this prospectus.
We will pay all of the expenses incident to the registration of the common
stock, other than underwriting discounts and selling commissions, if any. The
aggregate proceeds to the selling holders from the sale of the common stock will
be the purchase price of that common stock less any of these discounts or
commissions.
We have agreed to indemnify the selling stockholders against some of the
liabilities under the Securities Act of 1933 arising from this prospectus or the
registration statement of which it is a part.
EXPERTS
Our audited financial statements incorporated into this prospectus by
reference have been so incorporated in reliance upon the report of Gelfond
Hochstadt Pangburn, P.C., independent certified public accountants ("our
auditor"), which expresses an unqualified opinion and includes an explanatory
paragraph relating to our ability to continue as a going concern, given upon
their authority as experts in auditing and accounting.
With respect to our unaudited financial statements incorporated into this
prospectus by reference, our auditor has applied limited procedures in
accordance with professional standards for a review of such information.
However, as stated in their separate reports included in our quarterly report on
Form 10-QSB for the fiscal quarter ended September 30, 2004, and incorporated by
reference into this prospectus, our auditor did not audit and they do not
express an opinion on that interim financial information. Because of the
limited nature of the review procedures applied, the degree of reliance on our
auditor's reports on our interim financial information should be restricted.
Our auditor is not subject to the liability provisions of Section 11 of the
Securities Act of 1933 for their reports on our unaudited interim financial
information because those reports are not a "report" or a "part" of the
registration statement of which this prospectus forms a part prepared or
certified by our auditor within the meaning of Section 7 and 11 of the
Securities Act of 1933.
AVAILABLE INFORMATION
We are subject to the informational requirements of the Securities Exchange
Act of 1934 and, in compliance with this act, file periodic reports and other
information with the SEC. These reports and the other information we file with
the SEC can be inspected and copied at the public reference room facilities
maintained by the SEC in Washington, D.C. at 450 Fifth Street, N.W., Washington,
D.C. 20549. The SEC's telephone number to obtain information on the operation of
the public reference room is (800) SEC-0330. In addition, the SEC maintains a
World Wide Web site that contains reports, proxy statements
22
and other information regarding registrants like the company that file
electronically with the SEC at the following Internet address:
(http://www.sec.gov). The SEC's telephone number is (800) SEC-0330.
We have filed with the SEC in Washington, D.C. a registration statement on
Form S-2 under the Securities Act of 1933 with respect to the shares of our
common stock offered by this prospectus.
ADDITIONAL INFORMATION
This prospectus is part of a registration statement on Form S-2 that we
have filed with the SEC. This prospectus is only a part of that registration
statement, and does not contain all of the information that is included in the
registration statement, several sections of which are not included at all in
this prospectus. The statements contained in this prospectus, including
statements as to the contents of any contract or other document, are not
necessarily complete. You should refer to the registration statement and to an
actual copy of the contract or document filed as an exhibit to the registration
statement for more complete information. The registration statement may be
obtained from the SEC through one of the methods described above in "AVAILABLE
INFORMATION."
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference" the information we file
with them, which means that we can disclose important information to you by
referring you to those documents. The following documents filed with the SEC
are incorporated in this prospectus by reference:
- Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004
that was filed with the SEC on October 1, 2004;
- Current Report on Form 8-K that was filed with the SEC on October 5,
2004;
- Quarterly Report on Form 10-QSB for the quarter ended September 30,
2004 that was filed with the SEC on November 15, 2004;
- Current Report on Form 8-K that was filed with the SEC on November 19,
2004; and
- Current Report on Form 8-K that was filed with the SEC on December 1,
2004.
Our commission file number is 033-19598-D.
Any statement contained in a document incorporated or deemed to be
incorporated by reference into this prospectus shall be deemed to be modified or
superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus modifies or supersedes that statement or to the
extent that an amendment to an incorporated document modifies or supersedes the
incorporated document. Any statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a part of this
prospectus.
On request we will provide at no cost to each person, including any
beneficial owner, who receives a copy of this prospectus, a copy of any or all
of the documents incorporated in this prospectus by reference other than
exhibits to these documents. Requests for these copies should be directed to
Nanopierce Technologies, Inc., 370 17th Street, Suite 3640, Denver, Colorado
80202, telephone number (303) 592-1010, attention: Kristi J. Kampmann, email
address: kristi@nanopierce.com.
23
================================================================================
THE ONLY SOURCES OF INFORMATION GIVEN TO YOU BY US ABOUT YOUR INVESTMENT
DECISION ARE THIS PROSPECTUS AND ANY DOCUMENTS REFERRED TO IN THIS PROSPECTUS.
WE DID NOT AUTHORIZE ANYONE TO GIVE YOU ANY OTHER INFORMATION ABOUT YOUR
INVESTMENT DECISION.
THIS PROSPECTUS IS NOT AN OFFER TO SELL SECURITIES AND IS NOT MEANT TO
INDUCE THE SALE OF SECURITIES IF IT WOULD VIOLATE STATE LAW. IF THE PERSONS WHO
ARE TRYING TO OFFER THE SECURITIES FOR SALE, OR THE PERSONS WHO RECEIVE THOSE
OFFERS FOR SALE ARE PROHIBITED FROM DOING SO UNDER STATE LAW, THIS PROSPECTUS IS
NOT MEANT TO INDUCE SALE OF THE SECURITIES DESCRIBED IN THIS PROSPECTUS.
TABLE OF CONTENTS
Page
-----
FORWARD-LOOKING STATEMENTS. . . . . . . . . . . . . . . . . . . . . . . . . 2
PROSPECTUS SUMMARY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
RISK FACTORS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
THE COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
USE OF PROCEEDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
DETERMINATION OF OFFERING PRICE . . . . . . . . . . . . . . . . . . . . . . 14
SELLING STOCKHOLDERS. . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
DESCRIPTION OF COMMON STOCK . . . . . . . . . . . . . . . . . . . . . . . . 17
PLAN OF DISTRIBUTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
EXPERTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
AVAILABLE INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
ADDITIONAL INFORMATION. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
INCORPORATION OF CERTAIN
DOCUMENTS BY REFERENCE. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
================================================================================
82,600,000 SHARES OF COMMON STOCK
NANOPIERCE
TECHNOLOGIES, INC.
COMMON STOCK
---------------------
PROSPECTUS
---------------------
JANUARY 28, 2005
================================================================================